Stada CEO & CFO Resign; Rumors Circle Of A New Takeover bid
Stada's top brass have quit following rumors earlier this week of a fresh takeover bid for the generic company from equity groups Bain and Cinven; ex-Boehringer executive Tjeenk Willink has been named incoming CEO.
You may also be interested in...
There has been $150bn worth of merger and acquisition activity since 2012 in the generic medicines arena, yet the sector is more fragmented than it was five years ago. CEOs and analysts from the generics sector believe that investor-propelled moves towards greater consolidation have been thwarted by the market agility of smaller companies. And now the cost of M&A has burdened major generics firms with debt.
Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.